Nintedanib Ethanesulfonate Salt
|
尼達(dá)尼布乙磺酸鹽
|
656247-18-6
|
Alectinib Hydrochloride
|
艾樂(lè)替尼鹽酸鹽
|
1256589-74-8
|
PF-03814735
|
N-[2-[(1S,4R)-6-[[4-(環(huán)丁基氨基)-5-(三氟甲基)-2-嘧啶基]氨基]-1,2,3,4-四氫萘-1,4-亞氨-9-基]-2-氧代乙基]乙酰胺
|
942487-16-3
|
PRT062607 Hydrochloride
|
PRT062607 (HYDROCHLORIDE)
|
1370261-97-4
|
LDN-192960
|
3-[(2,7-二甲氧基吖啶-9-基)硫基]丙胺
|
184582-62-5
|
Mirk-IN-1
|
1386979-55-0
|
1386979-55-0
|
Orelabrutinib
|
奧布替尼
|
1655504-04-3
|
Pralsetinib
|
BLU-667(拉西替尼)
|
2097132-94-8
|
LDN-192960 hydrochloride
|
LDN-192960 HYDROCHLORIDE
|
2309172-48-1
|
UNC2025 hydrochloride
|
UNC2025 鹽酸鹽
|
2070015-17-5
|
AZM475271
|
476159-98-5
|
476159-98-5
|
Fostamatinib disodium hexahydrate
|
福他替尼鈉鹽水合物
|
914295-16-2
|
Cediranib maleate
|
西地尼布馬來(lái)酸鹽
|
857036-77-2
|
Flumatinib mesylate
|
甲磺酸氟馬替尼/氟馬替尼
|
895519-91-2
|
PRT-060318
|
PRT-060318
|
1194961-19-7
|
JH-VIII-157-02
|
化合物 T15612
|
1639422-97-1
|
SRI 31215 TFA
|
SRI-31215 BIS-TFA SALT
|
1832686-44-8
|
NVP-BHG712 isomer
|
NVP-BHG712 isomer
|
2245892-85-5
|
Tyrphostin AG1433
|
Tyrphostin AG1433
|
168835-90-3
|
DCC-3014
|
DCC3014
|
1628606-05-2
|
RET-IN-3
|
化合物 RET-IN-3
|
2414374-53-9
|
Cabozantinib S-malate
|
蘋(píng)果酸卡博替尼
|
1140909-48-3
|
JNJ-38877618
|
JNJ-38877618
|
943540-74-7
|
TAS-115 mesylate
|
TAS-115 MESYLATE
|
1688673-09-7
|
AZ-Dyrk1B-33
|
3-(2-Methyl-4-pyrimidinyl)-1-(phenylmethyl)-1H-pyrrolo[2,3-c]pyridine
|
1679330-37-0
|
Jaspamycin
|
JASPAMYCIN
|
22242-96-2
|
FGFR1/DDR2 inhibitor 1
|
FGFR1/DDR2 inhibitor 1
|
2308497-58-5
|
Nocodazole
|
諾考達(dá)唑
|
31430-18-9
|
ALK inhibitor 1
|
2-[[5-溴-2-[[2-甲氧基-4-(4-甲基-1-哌嗪基)苯基]氨基]-4-嘧啶基]氨基]-N-甲基苯磺酰胺
|
761436-81-1
|
VC-4718
|
PND1186
|
1061353-68-1
|
AZD7507
|
CS-2850
|
1041852-85-0
|
UNC2541
|
UNC2541
|
1612782-86-1
|
Y15
|
1,2,4,5-苯四胺四鹽酸鹽
|
4506-66-5
|
Pazopanib Hydrochloride
|
鹽酸帕唑帕尼
|
635702-64-6
|
R406
|
6-[[5-氟-2-[(3,4,5-三甲氧基苯基)氨基]-4-嘧啶基]氨基]-2,2-二甲基-2H-吡啶并[3,2-B]-1,4-惡嗪-3(4H)-酮苯磺酸鹽
|
841290-81-1
|
AC710
|
N-[4-[[[[5-(叔丁基)-3-異惡唑基]氨基]羰基]氨基]苯基]-5-[(1-乙基-2,2,6,6-四甲基-4-哌啶基)氧基]-2-吡啶甲酰胺
|
1351522-04-7
|
(Rac)-IBT6A
|
1412418-47-3
|
1412418-47-3
|
Brigatinib
|
布格替尼
|
1197953-54-0
|
ARQ 531
|
ARQ-531
|
2095393-15-8
|
Remibrutinib
|
LOU-064
|
1787294-07-8
|
BT-13
|
BT-13
|
924537-98-4
|
cFMS Receptor Inhibitor II
|
CFMS RECEPTOR INHIBITOR II
|
959860-85-6
|
Bozitinib
|
BOZITINIB (PLB-1001)
|
1440964-89-5
|
BAY-474
|
化合物BAY-474
|
1033767-86-0
|
WRG-28
|
WRG-28
|
1913291-02-7
|
BIIB068
|
BIIB068
|
1798787-27-5
|
BO-264
|
BO-264
|
2408648-20-2
|
Lyn-IN-1
|
巴非替尼
|
887650-05-7
|
Fostamatinib
|
福他替尼
|
901119-35-5
|
Infigratinib phosphate
|
NVP BGJ398 磷酸鹽
|
1310746-10-1
|
CP-547632 hydrochloride
|
CP-547632 (hydrochloride)
|
252003-71-7
|
MK-8033 hydrochloride
|
3-(1-甲基-1H-吡唑-4-基)-5-氧代-N-(2-吡啶基甲基)-5H-苯并[4,5]環(huán)庚三烯并[1,2-B]吡啶-7-甲烷磺酰胺鹽酸鹽
|
1283000-43-0
|
GDC-0834 Racemate
|
N-[3-[6-[[4-(1,4-二甲基-3-氧代-2-哌嗪基)苯基]氨基]-4,5-二氫-4-甲基-5-氧代-2-吡嗪基]-2-甲基苯基]-4,5,6,7-四氫苯并[B]噻吩-2-甲酰胺
|
1133432-46-8
|
SKLB4771
|
FLT3-IN-1
|
1370256-78-2
|
Gilteritinib hemifumarate
|
GILTERITINIB FUMARATE
|
1254053-84-3
|
S49076
|
CS-2684
|
1265965-22-7
|
MAZ51
|
CS-2885
|
163655-37-6
|
RU-301
|
RU-301
|
1110873-99-8
|
PDGFRα kinase inhibitor 1
|
PDGFRα kinase inhibitor 1
|
2209053-93-8
|
SPP-86
|
1-(1-Methylethyl)-3-(2-phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
|
1357349-91-7
|
BMS-509744
|
N-(5-((5-(4-乙?;哙?1-甲?;?-4-甲氧基-2-甲基苯基)硫基)噻唑-2-基)-4-(((3,3-二甲基丁烷-2-基)氨基)甲基)苯甲酰胺
|
439575-02-7
|
MK-8033
|
MK-8033
|
1001917-37-8
|
ALK inhibitor 2
|
2-[[5-氯-2-[[2-甲氧基-4-(4-甲基-1-哌嗪基)苯基]氨基]-4-嘧啶基]氨基]-N-甲基苯磺酰胺
|
761438-38-4
|
Lucitanib
|
德立替尼
|
1058137-23-7
|
Dubermatinib
|
TP-0903
|
1341200-45-0
|
PRN1008
|
瑞扎布魯替尼
|
1575596-29-0
|
Taletrectinib
|
DS-6051b
|
1505515-69-4
|
Lck Inhibitor
|
6-(2,6-二甲基苯基)-2-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-嘧啶并[5',4':5,6]嘧啶并[1,2-A]苯并咪唑-5(6H)-酮
|
847950-09-8
|
PLX647
|
10MG
|
873786-09-5
|
PRN694
|
1575818-46-0
|
1575818-46-0
|
Imatinib
|
伊馬替尼
|
152459-95-5
|
TL02-59
|
3-(6,7-dimethoxyquinazolin-4-yloxy)-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide
|
1315330-17-6
|
FN-1501
|
1429515-59-2
|
1429515-59-2
|
AZD3229 Tosylate
|
AZD3229 Tosylate
|
2248003-71-4
|
CLK-IN-T3
|
CLK inhibitor T3
(T3)
|
2109805-56-1
|
VEGFR-2-IN-6
|
帕唑帕尼雜質(zhì)3
|
444731-47-9
|
TAM-IN-2
|
TAM-IN-2
|
2135642-56-5
|
AGL-2263
|
AG 2263
|
638213-98-6
|
Syk-IN-1
|
1,2,4-Triazine-6-carboxamide, 3-[[(1R,2S)-2-aminocyclohexyl]amino]-5-(1H-indol-7-ylamino)-
|
1491150-77-6
|
Imatinib D8
|
伊馬替尼D8
|
1092942-82-9
|
CP-547632
|
3-[(4-溴-2,6-二氟芐基)氧基]-5-[3-[4-(吡咯烷-1-基)丁基]脲基]異噻唑-4-甲酰胺
|
252003-65-9
|
DPH
|
5-(3-(4-氟苯基)-1-苯基-1H-吡唑-4-基)咪唑烷-2,4-二酮
|
484049-04-9
|
BAY 61-3606 dihydrochloride
|
BAY 61-3606
|
648903-57-5
|
GDC-0834
|
CS-1263
|
1133432-49-1
|
GDC-0834 S-enantiomer
|
化合物 T11378
|
1133432-50-4
|
1-Naphthyl PP1 hydrochloride
|
1-叔丁基-3-(1-萘基)-1H-吡唑并[3,4-D]嘧啶-4-胺鹽酸鹽
|
956025-47-1
|
trans-Pralsetinib
|
cis-Pralsetinib hydrochloride (cis-BLU-667 hydrochloride)
|
2097132-93-7
|
Src Inhibitor 3
|
Src Inhibitor 3
|
2380027-49-4
|
Hck-IN-1
|
Nef-IN-B9
|
1473404-51-1
|
CA-4948
|
4-Oxazolecarboxamide, N-[5-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl]-2-(2-methyl-4-pyridinyl)-
|
1801344-14-8
|
RET V804M-IN-1
|
化合物RET V804M-IN-1
|
2414909-94-5
|
I-OMe-Tyrphostin AG 538
|
I-OME-AG 538
|
1094048-77-7
|
Pivanex
|
(2,2-二甲基-1-氧代丙氧基)丁酸甲酯
|
122110-53-6
|
Petunidin chloride
|
矮牽牛素PT
|
1429-30-7
|
TIE-2/VEGFR-2 kinase-IN-1
|
6-(4-甲氧基苯基)呋喃并[2,3-D]嘧啶-4-胺
|
453590-24-4
|
AG-13958
|
N-[2-氟-5-[[3-[(1E)-2-(2-吡啶基)乙烯基]-1H-吲唑-6-基]氨基]苯基]-1,3-二甲基-1H-吡唑-5-甲酰胺
|
319460-94-1
|
PF-04217903 methanesulfonate
|
PF 04217903 MESYLATE
|
956906-93-7
|
DDR1-IN-1
|
N-[3-[(2,3-二氫-2-氧代-1H-吲哚-5-基)氧基]-4-甲基苯基]-4-[(4-乙基-1-哌嗪基)甲基]-3-(三氟甲基)苯甲酰胺
|
1449685-96-4
|
CH6953755
|
CH6953755
|
2055918-71-1
|
Imatinib D4
|
[2H4]-伊馬替尼
|
1134803-16-9
|